Controversial ‘3-Parent Baby’ Fertility Technique Fails to Deliver for Older Women
By Emily Mullin,
Medium One Zero [cites CGS' Marcy Darnovsky]
| 10. 15. 2019
The experimental procedure is banned in the United States but is being offered at clinics abroad as a treatment for infertility.
An experimental and much-hyped reproductive procedure that mixes DNA from three people is not effective at boosting the chances of having a baby for women ages 37 and older, according to doctors at a fertility clinic in Ukraine.
The technique, known as mitochondrial replacement therapy, involves taking a woman’s egg and shifting the majority of its DNA, known as the nucleus, into a hollowed-out donor egg. The shell of the donor egg contains healthy mitochondria, energy-making structures that have their own DNA. The resulting embryo ends up with DNA from the mother, father, and egg donor, so the technique is often referred to as “three-person IVF.” The procedure is controversial because many consider it a form of genetic manipulation.
Some fertility experts hoped that the younger mitochondria from the hollowed-out donor egg might rejuvenate the eggs of an infertile woman, thus increasing the chances of a successful pregnancy.
But new study results presented at a meeting of the American Society of Reproductive Medicine in Philadelphia show that might not be the case. The three-person IVF procedure was found to be...
Related Articles
By Bernice Lottering, Gene Online | 11.08.2024
South Africa’s updated health-research ethics guidelines, which now include heritable human genome editing, have sparked concern among scientists. The revisions, made in May but only recently gaining attention, outline protocols for modifying genetic material in sperm, eggs, or embryos—changes...
By Jim Thomas, Scan the Horizon | 11.19.2024
It’s the wee hours of 2nd November 2024 in Cali, Colombia. In a large UN negotiating hall Colombian Environment Minister Susana Muhamed has slammed down the gavel on a decision that should send a jolt through the AI policy world. ...
By Ned Pagliarulo, BioPharmaDive | 11.05.2024
A medicine built around a more precise form of CRISPR gene editing appeared to work as designed in its first clinical trial test, developer Beam Therapeutics said Tuesday. But the death of a trial participant could renew concerns about an older...
By Ruth Retassie, PET | 10.21.2024